Literature DB >> 30760520

Transcriptomics Associates Molecular Features with 18F-Fluorocholine PET/CT Imaging Phenotype and Its Potential Relationship to Survival in Hepatocellular Carcinoma.

Sandi A Kwee1,2, Maarit Tiirikainen2, Miles M Sato3, Jared D Acoba2,3, Runmin Wei2, Wei Jia2, Loic Le Marchand2, Linda L Wong2,4.   

Abstract

Studies involving transcriptomics have revealed multiple molecular subtypes of hepatocellular carcinoma (HCC). Positron emission tomography/computed tomography (PET/CT) has also identified distinct molecular imaging subtypes, including those with increased and decreased choline metabolism as measured by the tissue uptake of the radiopharmaceutical 18F-fluorocholine. Gene signatures reflecting the molecular heterogeneity of HCC may identify the biological and clinical significance of these imaging subtypes. In this study, 41 patients underwent 18F-fluorocholine PET/CT, followed by tumor resection and gene expression profiling. Over- and underexpressed components of previously published gene signatures were evaluated for enrichment between tumors with high and low 18F-fluorocholine uptake using gene set analysis. Significant gene sets were enumerated by FDR based on phenotype permutation. Associations with overall survival were analyzed by univariate and multivariate proportional hazards regression. Ten gene sets related to HCC were significantly associated with high tumor 18F-fluorocholine uptake at FDR q < 0.05, including those from three different clinical molecular classification systems and two prognostic signatures for HCC that showed predictive value in the study cohort. Tumor avidity for 18F-fluorocholine was associated with favorable characteristics based on these signatures with lower mortality based on survival analysis (HR 0.36; 95% confidence interval, 0.14-0.95). Tumors demonstrating high 18F-fluorocholine uptake were also enriched for genes involved in oxidative phosphorylation, fatty acid metabolism, peroxisome, bile acid metabolism, xenobiotic metabolism, and adipogenesis. These results provide a pathobiological framework to further evaluate 18F-fluorocholine PET/CT as a molecular and prognostic classifier in HCC. SIGNIFICANCE: A pathobiological framework for HCC brings together multiple prognostically relevant gene signatures via convergence with 18F-fluorocholine PET/CT imaging phenotype. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30760520      PMCID: PMC6494445          DOI: 10.1158/0008-5472.CAN-18-3837

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  42 in total

1.  The end of almost 10 years of negative RCTs in advanced hepatocellular carcinoma.

Authors:  Jean-Charles Nault
Journal:  Lancet       Date:  2016-12-06       Impact factor: 79.321

2.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.

Authors:  Jorge A Marrero; Laura M Kulik; Claude B Sirlin; Andrew X Zhu; Richard S Finn; Michael M Abecassis; Lewis R Roberts; Julie K Heimbach
Journal:  Hepatology       Date:  2018-08       Impact factor: 17.425

3.  Consequences of needle tract seeding of hepatocellular cancer after liver transplant.

Authors:  Kristi T Lopez; Scott K Kuwada; Linda L Wong
Journal:  Clin Transplant       Date:  2013-07-10       Impact factor: 2.863

4.  Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets.

Authors:  Sandrine Boyault; David S Rickman; Aurélien de Reyniès; Charles Balabaud; Sandra Rebouissou; Emmanuelle Jeannot; Aurélie Hérault; Jean Saric; Jacques Belghiti; Dominique Franco; Paulette Bioulac-Sage; Pierre Laurent-Puig; Jessica Zucman-Rossi
Journal:  Hepatology       Date:  2007-01       Impact factor: 17.425

Review 5.  Choline metabolism in malignant transformation.

Authors:  Kristine Glunde; Zaver M Bhujwalla; Sabrina M Ronen
Journal:  Nat Rev Cancer       Date:  2011-11-17       Impact factor: 60.716

6.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

7.  Clinicopathological indices to predict hepatocellular carcinoma molecular classification.

Authors:  Poh Seng Tan; Shigeki Nakagawa; Nicolas Goossens; Anu Venkatesh; Tiangui Huang; Stephen C Ward; Xiaochen Sun; Won-Min Song; Anna Koh; Claudia Canasto-Chibuque; Manjeet Deshmukh; Venugopalan Nair; Milind Mahajan; Bin Zhang; Maria Isabel Fiel; Masahiro Kobayashi; Hiromitsu Kumada; Yujin Hoshida
Journal:  Liver Int       Date:  2015-06-29       Impact factor: 5.828

8.  PET imaging of hepatocellular carcinoma with 2-deoxy-2[18F]fluoro-D-glucose, 6-deoxy-6[18F] fluoro-D-glucose, [1-11C]-acetate and [N-methyl-11C]-choline.

Authors:  N Salem; Y Kuang; F Wang; G T Maclennan; Z Lee
Journal:  Q J Nucl Med Mol Imaging       Date:  2008-11-28       Impact factor: 2.346

9.  Minimum lesion detectability as a measure of PET system performance.

Authors:  Stephen Adler; Jurgen Seidel; Peter Choyke; Michael V Knopp; Katherine Binzel; Jun Zhang; Craig Barker; Shielah Conant; Roberto Maass-Moreno
Journal:  EJNMMI Phys       Date:  2017-03-04

10.  Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma.

Authors:  Yujin Hoshida; Sebastian M B Nijman; Masahiro Kobayashi; Jennifer A Chan; Jean-Philippe Brunet; Derek Y Chiang; Augusto Villanueva; Philippa Newell; Kenji Ikeda; Masaji Hashimoto; Goro Watanabe; Stacey Gabriel; Scott L Friedman; Hiromitsu Kumada; Josep M Llovet; Todd R Golub
Journal:  Cancer Res       Date:  2009-09-01       Impact factor: 12.701

View more
  5 in total

1.  Addition of [18 F]Fluorodeoxyglucose Positron Emission Tomography With Computed Tomography to Cross-Sectional Imaging Improves Staging and Alters Management in Hepatocellular Carcinoma.

Authors:  Binu V John; Sean Aubuchon; Bassam Dahman; Venkata Rajesh Konjeti; Douglas Heuman; Jennifer Hubert; Smitha Thomas; Yangyang Deng; Cynthia Solomon; Latha Thankam Sundaram; Eleanor Love; Amit G Singal; James L Tatum
Journal:  Liver Transpl       Date:  2020-05-08       Impact factor: 5.799

2.  Beta-catenin activation and immunotherapy resistance in hepatocellular carcinoma: mechanisms and biomarkers.

Authors:  Sandi A Kwee; Maarit Tiirikainen
Journal:  Hepatoma Res       Date:  2021-01-07

3.  Identification of immune landscape signatures associated with clinical and prognostic features of hepatocellular carcinoma.

Authors:  Hongmei Yan; Yuchuan Chen; Kai Wang; Lu Yu; Xixin Huang; Qianyu Li; Yuwen Xie; Jiayu Lin; Yueyun He; Xinyu Yi; Yanzhi Wang; Longhua Chen; Yi Ding; Yiyi Li
Journal:  Aging (Albany NY)       Date:  2020-10-13       Impact factor: 5.682

4.  Consideration of Metabolite Efflux in Radiolabelled Choline Kinetics.

Authors:  Yunqing Li; Marianna Inglese; Suraiya Dubash; Chris Barnes; Diana Brickute; Marta Costa Braga; Ning Wang; Alice Beckley; Kathrin Heinzmann; Louis Allott; Haonan Lu; Cen Chen; Ruisi Fu; Laurence Carroll; Eric O Aboagye
Journal:  Pharmaceutics       Date:  2021-08-12       Impact factor: 6.321

5.  Phospholipids are A Potentially Important Source of Tissue Biomarkers for Hepatocellular Carcinoma: Results of a Pilot Study Involving Targeted Metabolomics.

Authors:  Erin B Evangelista; Sandi A Kwee; Miles M Sato; Lu Wang; Christoph Rettenmeier; Guoxiang Xie; Wei Jia; Linda L Wong
Journal:  Diagnostics (Basel)       Date:  2019-10-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.